WallStreetZenWallStreetZen

NASDAQ: IPA
Immunoprecise Antibodies Ltd Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

IPA past revenue growth

How has IPA's revenue growth performed historically?
Company
16.75%
Industry
149.3%
Market
17.29%
IPA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
IPA's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
IPA's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

IPA earnings and revenue history

Current Revenue
$17.7M
Current Earnings
-$10.6M
Current Profit Margin
-60.2%

IPA Return on Equity

Current Company
-26.7%
Current Industry
-63.5%
Current Market
188%
IPA's Return on Equity (-26.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when IPA announces earnings.

IPA Return on Assets

Current Company
-18.5%
Current Industry
2.9%
IPA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

IPA Return on Capital Employed

Current Company
-22.66%
Current Industry
19.5%
IPA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

IPA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
IPA$17.41M-$7.05M-$10.48M+68.89%N/A
ICU$0.00-$25.15M-$26.23MN/AN/A
EVGN$5.64M-$20.34M-$23.88M+26.41%N/A
VYNE$424.00k-$28.45M-$28.45M-34.79%N/A
CASI$33.88M-$22.29M-$26.96M+69.23%N/A
View Top Biotech Stocks

Immunoprecise Antibodies Earnings & Revenue FAQ

What were IPA's earnings last quarter?

On Invalid Date, Immunoprecise Antibodies (NASDAQ: IPA) reported Q4 2023 earnings per share (EPS) of -$0.08, up 42.25% year over year. Total Immunoprecise Antibodies earnings for the quarter were -$2.19 million. In the same quarter last year, Immunoprecise Antibodies's earnings per share (EPS) was -$0.14.

If you're new to stock investing, here's how to buy Immunoprecise Antibodies stock.

What was IPA's earnings growth in the past year?

As of Q2 2024, Immunoprecise Antibodies's earnings has grown year over year. Immunoprecise Antibodies's earnings in the past year totalled -$10.48 million.

What was IPA's revenue last quarter?

On Invalid Date, Immunoprecise Antibodies (NASDAQ: IPA) reported Q4 2023 revenue of $4.64 million up 20.31% year over year. In the same quarter last year, Immunoprecise Antibodies's revenue was $3.86 million.

What was IPA's revenue growth in the past year?

As of Q2 2024, Immunoprecise Antibodies's revenue has grown 16.75% year over year. This is 132.55 percentage points lower than the US Biotechnology industry revenue growth rate of 149.3%. Immunoprecise Antibodies's revenue in the past year totalled $17.41 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.